Binx Health
Total Raised
$203.5MInvestors Count
20Deal Terms
2Funding, Valuation & Revenue
8 Fundings
Binx Health's latest funding round was a Series E for $104M on May 27, 2021.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
5/27/2021 | Series E | $104M | 8 | |||
11/10/2020 | Series D - II | |||||
1/23/2017 | Series D | |||||
1/29/2015 | Series C | |||||
4/29/2014 | Series B - II |
Date | 5/27/2021 | 11/10/2020 | 1/23/2017 | 1/29/2015 | 4/29/2014 |
|---|---|---|---|---|---|
Round | Series E | Series D - II | Series D | Series C | Series B - II |
Amount | $104M | ||||
Investors | |||||
Valuation | |||||
Revenue | |||||
Sources | 8 |
This profile has not been claimed.
You're more than your latest funding, tell our customers your company's story.
Binx Health Deal Terms
2 Deal Terms
Binx Health's deal structure is available for 2 funding rounds, including their Series B from July 20, 2011.
Round | Series B | Series A |
|---|---|---|
Funding Date | ||
Pre-Money Valuation | ||
Post-Money Valuation | ||
Amount Raised | ||
Shares Authorized | ||
Issuance Price | ||
Dividend Rate | ||
Liquidation Preferences | ||
Liquidation Price | ||
Participation | ||
Conversion Price | ||
Anti Dilution | ||
General Voting | ||
Board Voting | ||
Par Value |
Round | Funding Date | Pre-Money Valuation | Post-Money Valuation | Amount Raised | Shares Authorized | Issuance Price | Dividend Rate | Liquidation Preferences | Liquidation Price | Participation | Conversion Price | Anti Dilution | General Voting | Board Voting | Par Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Series B | |||||||||||||||
Series A |
Binx Health Investors
20 Investors
Binx Health has 20 investors. EQT Life Sciences invested in Binx Health's Series E funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
7/20/2011 | 5/27/2021 | 5 Series B, Series B - II (2014), Series C (2015), Series D (2017), Series E (2021) | Venture Capital | Netherlands | ||
7/20/2011 | 5/27/2021 | 5 Series B, Series B - II (2014), Series C (2015), Series D (2017), Series E (2021) | Corporate Venture | New Jersey | ||
11/10/2020 | 5/27/2021 | 2 Series D - II, Series E (2021) | Venture Capital | Spain | ||
Asset/Investment Management | Colorado | |||||
Family Office | New York |
First funding | 7/20/2011 | 7/20/2011 | 11/10/2020 | ||
|---|---|---|---|---|---|
Last Funding | 5/27/2021 | 5/27/2021 | 5/27/2021 | ||
Investor | |||||
Rounds | 5 Series B, Series B - II (2014), Series C (2015), Series D (2017), Series E (2021) | 5 Series B, Series B - II (2014), Series C (2015), Series D (2017), Series E (2021) | 2 Series D - II, Series E (2021) | ||
Board Seats | |||||
Type | Venture Capital | Corporate Venture | Venture Capital | Asset/Investment Management | Family Office |
Location | Netherlands | New Jersey | Spain | Colorado | New York |
Compare Binx Health to Competitors
Coyote Bioscience is dedicated to the development of portability of point-of-care molecular diagnostics, pathogen detection, and life science tools.
Visby Medical is transforming the order of diagnosis and treatment for infectious diseases so clinicians can test, talk with, and treat the patient in a single visit. The company’s technology development program culminated in an instrument-free, single-use PCR platform that rapidly tests for serious infections. Originally developed for sexually transmitted infections, the Company’s FDA-cleared, CLIA-waived Sexual Health Click Test for women returns accurate results within 28 minutes. Visby Medical technology also offers the Visby Medical COVID-19 Test, and its robust pipeline includes tests for other infectious diseases. It was founded in 2015 and is based in San Jose, California.
52 North Health develops NeutroCheck which is a fully-integrated clinical, AI- and medical device-based system for people living with cancer. It is a point-of-care medical device that can be used by patients outside of the hospital to monitor their risk of neutropenic sepsis, a potentially life-threatening complication of chemotherapy. The company was formerly known as Neutrocheck It was founded in 2018 and is based in Cambridge, U.K.
Ultrasight develops an automated ultrasound solution that provides AI-based navigation, analysis, and diagnosis at the point of care.
Module Innovations is a low-cost portable point-of-care diagnostic device for microbial infections like Urinary Tract Infections (UTI). The company leverages the strength of nano & bio, to create products in healthcare.
RICOVR Healthcare is the creator of the XALIVA rapid diagnostics platform that provides high-quality, rapid diagnostics results using a small amount of saliva. The company’s product pipeline includes rapid point-of-care tests for Covid-19, THC & drugs-of-abuse, and infectious diseases. The company's patented biosensor platform uses a small drop of saliva to provide high-quality, cost-effective results in approximately five minutes, enabling employers, healthcare systems, and law enforcement to carry out cost-effective, non- invasive workplace and roadside testing.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.